André Elferink

570 total citations
16 papers, 278 citations indexed

About

André Elferink is a scholar working on Economics and Econometrics, Pediatrics, Perinatology and Child Health and Pharmacology. According to data from OpenAlex, André Elferink has authored 16 papers receiving a total of 278 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Economics and Econometrics, 4 papers in Pediatrics, Perinatology and Child Health and 3 papers in Pharmacology. Recurrent topics in André Elferink's work include Health Systems, Economic Evaluations, Quality of Life (4 papers), Pharmaceutical Economics and Policy (4 papers) and Treatment of Major Depression (3 papers). André Elferink is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (4 papers), Pharmaceutical Economics and Policy (4 papers) and Treatment of Major Depression (3 papers). André Elferink collaborates with scholars based in Netherlands, Germany and Poland. André Elferink's co-authors include Jitschak G. Storosum, Barbara J. van Zwieten, Tamar Wohlfarth, Wim van den Brink, Christine C. Gispen‐de Wied, Marion Haberkamp, Berthold P. R. Gersons, André W. Broekmans, R. van Strik and Armando Magrelli and has published in prestigious journals such as The Lancet, American Journal of Psychiatry and Drug Discovery Today.

In The Last Decade

André Elferink

14 papers receiving 255 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
André Elferink Netherlands 9 79 70 56 41 35 16 278
Louise Schow Guski Denmark 7 105 1.3× 100 1.4× 104 1.9× 27 0.7× 21 0.6× 8 350
Tyra Lagerberg United Kingdom 11 92 1.2× 36 0.5× 80 1.4× 35 0.9× 31 0.9× 32 299
C. Bruce Baker United States 9 135 1.7× 70 1.0× 35 0.6× 103 2.5× 26 0.7× 12 349
Tom Denee United Kingdom 7 82 1.0× 125 1.8× 47 0.8× 26 0.6× 9 0.3× 21 266
Michaela Strobelberger United States 7 120 1.5× 178 2.5× 37 0.7× 27 0.7× 13 0.4× 13 388
Aditi Kadakia United States 9 156 2.0× 33 0.5× 34 0.6× 15 0.4× 30 0.9× 22 303
Christian G. Widschwendter Austria 10 211 2.7× 42 0.6× 68 1.2× 34 0.8× 18 0.5× 19 328
Lovisa Berggren United States 13 178 2.3× 103 1.5× 31 0.6× 19 0.5× 23 0.7× 27 392
Patricia L. Gilbert United States 3 305 3.9× 43 0.6× 101 1.8× 25 0.6× 26 0.7× 5 352
Holly Crudgington United Kingdom 7 54 0.7× 105 1.5× 30 0.5× 14 0.3× 54 1.5× 11 209

Countries citing papers authored by André Elferink

Since Specialization
Citations

This map shows the geographic impact of André Elferink's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by André Elferink with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites André Elferink more than expected).

Fields of papers citing papers by André Elferink

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by André Elferink. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by André Elferink. The network helps show where André Elferink may publish in the future.

Co-authorship network of co-authors of André Elferink

This figure shows the co-authorship network connecting the top 25 collaborators of André Elferink. A scholar is included among the top collaborators of André Elferink based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with André Elferink. André Elferink is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Bakker, Elisabeth, Viktoriia Starokozhko, André Elferink, et al.. (2025). Biomarkers for neurodegenerative diseases in regulatory decision‐making by the European Medicines Agency. Alzheimer s & Dementia Translational Research & Clinical Interventions. 11(1). e70072–e70072. 1 indexed citations
2.
Browne, K, Ewa Bałkowiec-Iskra, André Elferink, et al.. (2025). Applying the EU Regulatory Framework to Determine the Benefit–Risk Profile of Psychedelics. ACS Pharmacology & Translational Science. 8(8). 2830–2838.
3.
Mavridis, Dimitris, Stavros Nikolakopoulos, André Elferink, et al.. (2024). Do efficacy results obtained from randomized controlled trials translate to effectiveness data from observational studies for relapsing–remitting multiple sclerosis?. Pharmacoepidemiology and Drug Safety. 33(5). e5810–e5810.
4.
Butlen‐Ducuing, Florence, Marion Haberkamp, Ewa Bałkowiec-Iskra, et al.. (2023). The therapeutic potential of psychedelics: the European regulatory perspective. The Lancet. 401(10378). 714–716. 20 indexed citations
5.
Butlen‐Ducuing, Florence, et al.. (2023). The new European Medicines Agency guideline on antidepressants: a guide for researchers and drug developers. European Psychiatry. 67(1). e2–e2. 8 indexed citations
6.
Haberkamp, Marion, Dimitrios Athanasiou, F Andrés-Trelles, et al.. (2019). European regulators’ views on a wearable-derived performance measurement of ambulation for Duchenne muscular dystrophy regulatory trials. Neuromuscular Disorders. 29(7). 514–516. 42 indexed citations
7.
Teerenstra, Steven, et al.. (2017). European regulatory use and impact of subgroup evaluation in marketing authorisation applications. Drug Discovery Today. 22(12). 1760–1764. 2 indexed citations
8.
Balabanov, Pavel, Manuel Haas, André Elferink, Serge Bakchine, & Karl Broich. (2014). Addressing the regulatory and scientific challenges in multiple sclerosis – a statement from the EU regulators. Multiple Sclerosis Journal. 20(10). 1282–1287. 7 indexed citations
9.
Maliepaard, Marc, et al.. (2011). Interchangeability of generic anti-epileptic drugs: a quantitative analysis of topiramate and gabapentin. European Journal of Clinical Pharmacology. 67(10). 1007–1016. 19 indexed citations
10.
Elferink, André, et al.. (2010). Insomnia medication: Do published studies reflect the complete picture of efficacy and safety?. European Neuropsychopharmacology. 21(7). 500–507. 15 indexed citations
11.
Maliepaard, Marc, Yechiel A. Hekster, A.C. Kappelle, et al.. (2010). Switching to generic anti-epileptic medicines : A regulatory perspective. University of Groningen research database (University of Groningen / Centre for Information Technology). 70(6). 918–931. 1 indexed citations
12.
Maliepaard, Marc, Yechiel A. Hekster, A.C. Kappelle, et al.. (2009). Requirements for generic anti-epileptic medicines: a regulatory perspective. Journal of Neurology. 256(12). 1966–1971. 6 indexed citations
13.
Storosum, Jitschak G., Tamar Wohlfarth, Aart H. Schene, et al.. (2007). Magnitude of effect of lithium in short‐term efficacy studies of moderate to severe manic episode. Bipolar Disorders. 9(8). 793–798. 31 indexed citations
14.
Wohlfarth, Tamar, et al.. (2005). Antidepressants use in children and adolescents and the risk of suicide. European Neuropsychopharmacology. 16(2). 79–83. 34 indexed citations
15.
Wohlfarth, Tamar, et al.. (2004). Response to Tricyclic Antidepressants: Independent of Gender?. American Journal of Psychiatry. 161(2). 370–372. 40 indexed citations
16.
Storosum, Jitschak G., André Elferink, Barbara J. van Zwieten, et al.. (2001). Short-term efficacy of tricyclic antidepressants revisited: a meta-analytic study. European Neuropsychopharmacology. 11(2). 173–180. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Louise Schow Guski Breakdown of academic impact, for papers by Tyra Lagerberg Breakdown of academic impact, for papers by C. Bruce Baker Breakdown of academic impact, for papers by Tom Denee Breakdown of academic impact, for papers by Michaela Strobelberger Breakdown of academic impact, for papers by Aditi Kadakia Breakdown of academic impact, for papers by Christian G. Widschwendter Breakdown of academic impact, for papers by Lovisa Berggren Breakdown of academic impact, for papers by Patricia L. Gilbert Breakdown of academic impact, for papers by Holly Crudgington
Rankless by CCL
2026